PT-141 in Men: What Erectile-Dysfunction Studies Exist

Short answer

Published human research in men exists. Vyleesi is not FDA-indicated for men. Those two sentences must stay together. One does not cancel the other.

This page summarizes design and limits. It does not supply doses, timing, reconstitution, or a combination protocol. Trial numbers are not turned into instructions.

2004 intranasal study

Diamond and colleagues published a 2004 double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties, and pharmacodynamic effects of intranasal PT-141. The population included healthy men and men with mild-to-moderate erectile dysfunction. The measured outcome was an objective erectile response.¹

That work is early human pharmacology. It does not create an FDA-approved male indication.⁵

2004 subcutaneous study

Rosen and colleagues also published, in 2004, an evaluation of the safety, pharmacokinetics, and pharmacodynamic effects of subcutaneously administered PT-141. The population included healthy men and patients reporting an inadequate response to sildenafil. The frame remains early human pharmacology and erectile response.²

The fact that a study mentions sildenafil does not authorize a combination protocol. It only describes who was enrolled.

2005 sildenafil combination study

Diamond and colleagues published a 2005 study of co-administration of low doses of intranasal PT-141 and sildenafil. Nineteen men with erectile dysfunction participated. The design was a small randomized crossover with a mechanistic character.³

Nineteen participants do not support a clinical recommendation, a stack, or timing guidance. This page does not reproduce those administration details.

2008 randomized trial

Safarinejad and Hosseini published a 2008 randomized, double-blind, placebo-controlled study of intranasal bremelanotide versus placebo. Three hundred forty-two men participated. The paper’s frame was salvage of sildenafil failures.⁴

That size is meaningful male human evidence. It still does not create an approved indication in men. Current Vyleesi labeling states the product is not indicated for HSDD in men and is not indicated to enhance sexual performance.⁵

Map of the studies in men

Reading these four papers on one page does not turn them into a continuous program. The route, the size, the year, and the question change. The 2004 intranasal study is not the same year’s subcutaneous study. The 19-man crossover is not the 342-man trial. None of them is the Vyleesi file. The temptation to “stack” them into a male indication is exactly what this page cuts.^1,2,3,4

An objective erectile-response measure is a study endpoint. It describes what the protocol recorded under those conditions. It does not authorize use guidance, does not set an interval, does not recommend a combination, and does not update the 2019 label. The label still says Vyleesi is not indicated for men and is not indicated to enhance sexual performance.⁵

The 2005 study deserves its own paragraph because it is easy to misread. Nineteen men and a mechanistic crossover can be cited as evidence that a co-administration was investigated. They cannot be cited as a protocol. This page names the design and the size. It does not reproduce doses, order, or timing. A small study is not scaled into a recommendation.³

Mentioning sildenafil in an enrollment criterion or a study arm describes the population. It does not write a combination for the reader. Rosen’s work included patients reporting an inadequate response to sildenafil. Diamond’s crossover investigated a co-administration. Neither becomes a recipe here. The mention stays in the design.^2,3

The 342-man trial is the easiest to overstate because the number looks like “enough evidence.” It is meaningful male human evidence. It remains a historical erectile-dysfunction study, not an approval. FDA did not take that paper and write a male indication onto Vyleesi. Confusing size with approval is the error generic content makes.^4,5

This literature is also not transferred to a research lyophilizate. The studies used preparations and routes from a clinical program. Peptra was not an arm. A certificate that reports PT-141 10mg, HPLC-UV, and an intact mass does not inherit an erectile response measured in 2004 or 2008. Published pharmacology stays published. The vial stays an analytical material.

What these studies establish

• Published human pharmacology in men exists.
• Objective erectile-response signals appear in early designs and in a 342-man trial.
• The 2005 study is a small crossover, not a combination program.

What they do not establish

• They do not establish a current FDA approval for men.
• They do not establish long-term safety for broad male use.
• They do not establish general male sexual enhancement.
• They do not establish efficacy of Peptra research material.
• They do not turn Vyleesi into an approved erectile-dysfunction treatment.

If a later headline claims a broad approval for sexual dysfunction, it will have widened the indication until it is false. Vyleesi’s approved indication is acquired generalized HSDD in premenopausal women. Research in men exists and is cited here. Those two sentences are not averaged. They stay in separate columns because the editorial harm appears when they fuse.⁵

The same harm appears when a text takes the 19-man study and turns it into a stack. The paper exists. The protocol does not. This page leaves the sample size in view so that no one forgets it. Nineteen participants inform a crossover. They do not inform a practice.³

Next reading

• Read the Phase 3 evidence in women
• Keep the peptide separate from the approved product
• Back to the research hub